The Companies Plan to Focus On Voltron’s VaxCelerate Vaccine Platform’s Effectiveness and Utility in a Variety of Tumor Settings
Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced a strategic development agreement with Translational Drug Development (TD2), a precision oncology contract research organization (CRO).
Over time the two companies plan to focus on Voltron’s VaxCelerate vaccine platform’s effectiveness and utility in a variety of tumor settings. The mutual effort is designed to evaluate several development and regulatory strategies, including pre-clinical work, indication/patient population selection, trial site selection and supporting Voltron’s initial BLA submission.
“Voltron is excited to have forged a relationship with TD2 to best leverage and develop our novel vaccine platform, VaxCelerate. We believe TD2’s wide ranging expertise in oncology, from trial design and execution to regulatory strategy across all cancer types, will help Voltron create differentiating data to bring more effective treatments to market in less time. Our highly experienced operations team was instrumental in the selection process and was extremely impressed with TD2’s capabilities, track record and responsiveness. Our initial project will focus on VaxCelerate in the ovarian cancer setting with additional consideration being given to potential future opportunities in NSCLC, pancreatic cancer, head and neck cancer and mesothelioma,” said Pat Gallagher, Managing Partner at LVP and CEO of Voltron.
“TD2 is honored to be selected to work with the great team at Voltron to accelerate this novel self-assembling vaccine medicine to help patients with ovarian and other cancers,” said Stephen Gately, CEO at TD2. “We look forward to deploying our full translational oncology service offerings to support all needed aspects of development with a key focus on the clinical and regulatory strategy to select patients most likely to gain clinical benefit.”
“It continues to be an exciting time of growth for Laidlaw Venture Partners, and in particular, our portfolio company Voltron Therapeutics. In past months, we have announced the addition of numerous world class healthcare professionals to our team. Today’s Voltron news is a result of leveraging that team’s experience, varied skill sets and invaluable relationships forged over decades of specialized work in the medical field,” said James Ahern, Founding Partner, Laidlaw Venture Partners.
